Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation

Eligibility Criteria

• 1. Pathologically confirmed solid tumor malignancies which are locally advanced or metastatic.
• 2. Able to safely receive intended protocol defined SBRT dose.
• 3. For oligometastatic category, patients can have up to 6 sites of active extracranial disease amenable to SBRT with a maximum of 7 cm diameter
• 4. Must have a CT C/A/P, or PET/CT scan within 12 weeks of enrollment.
• 5. Age ≥ 18 years.
• 6. Karnofsky performance status of 70 or higher, or ECOG \< 2
• 7. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• 7.1 a female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
• * Has not undergone a hysterectomy or bilateral oophorectomy; or
• * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
• 8. Negative urine or serum pregnancy test for women of child-bearing potential
• 9. Agreeable and willing to participate in expected protocol defined follow-up.
• 10. Ability to understand and the willingness to sign a written informed consent.
• 11. Registry participation does not exclude participation in clinical trials.
• 2. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.